A myriad of blows: Who's getting hit the hardest by the economy's troubles

The downturn shows few signs of hurting large pharma, but small biotechs and generics makers could face a credit crunch.

By Kim Ribbink • June 27, 2022

From vineyards to antivirals, Gilly Regev brings creative thinking to science

The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.

By Alexandra Pecci • June 27, 2022

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

4 tips for landing your next C-suite role in pharma

Even execs get the blues — and when they’re ready for a fresh start, Leslie Loveless, CEO of Slone Partners, says these dos and don’ts could make or break their next job move.

By Meagan Parrish • June 23, 2022

'Nobel Prize of pharma' helps put Huma's digital health platform on the global map

The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

By Kim Ribbink • June 23, 2022

#DIA2022: Building 'guardrails' in the FDA's accelerated approval program

Regulatory experts weigh in on ways to enhance the controversial drug approval approach.

By Karissa Waddick • June 21, 2022

The public health sleuth

In her decades-long career, Mary Pittman, CEO of the Public Health Institute, has seen — and helped solve — one public health mystery after another.

By Alexandra Pecci • June 21, 2022

#DIA2022: How the industry's top regulator views the future of healthcare

In the evolution of healthcare, data is the linchpin to making drug development more efficient.

By Michael Gibney • June 21, 2022

A patient-funded ALS drug offers hope where few treatments exist

Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.

By Kelly Bilodeau • June 15, 2022

TikTok tutorial: How pharma can embrace the video platform's educational potential

Ogilvy Health’s director of social strategy, Katie Ferrigno, busts myths and provides tips on how biopharmas can take advantage of TikTok’s unique features to connect with patients.

By Karissa Waddick • June 15, 2022

Woman of the Week: Tango Therapeutics' Dr. Barbara Weber

A pioneer in genetic medicine, Dr. Barbara Weber continues to push the envelope to expand the reach of therapies based on genetic targeting.

By Taren Grom • June 14, 2022

Buoyed by COVID-19 shot, J&J's vaccines head sees a new golden age approaching

Janssen’s goal to have ‘a vaccine for the world’ is part of what drew Penny Heaton to the company and its work.

By Alexandra Pecci • June 14, 2022

Making moves: Civica, Astellas, Inozyme and more announce key new hires

The latest hiring moves from Civica, Astella, Inozyme and the Flagship Pioneering-founded Tessera Therapeutics. 

By Karissa Waddick • June 13, 2022

How to boost utilization of your copay program

Give your copay program the gift of awareness. GoodRx provides a better way to effective programs

June 13, 2022

A combo of precision meds and diagnostics could disrupt mental healthcare

HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

By Kelly Bilodeau • June 8, 2022

As cancer innovations thrive, patient access is the next piece of the puzzle

Why enhanced clinical trials and diagnostics are keys to boosting patient access to cancer care.

By Michael Gibney • June 8, 2022

Woman of the Week: Janssen’s Najat Khan

Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.

By Taren Grom • June 8, 2022

Pharma giants take on Appalachian cancer rates in newest screening initiative

AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.

By Karissa Waddick • June 7, 2022

First 90 Days: Janssen Immunology’s David Jimenez

The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

By Taren Grom • June 6, 2022

How to build a cancer pipeline: Big Pharma oncology heads on driving science forward

Executives leading the cancer departments at J&J, Merck and Takeda chime in on what it takes to construct a successful and sustainable oncology drug pipeline.

By Michael Gibney • June 6, 2022

Aduhelm's Medicare woes leave questions about lofty premiums

A single drug’s effect on the premiums that Medicare beneficiaries pay is raising questions about how these levels are set and what factors play a part.

By Kelly Bilodeau • June 2, 2022

Flagship's creative approach to finding the next big idea in biopharma

Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.

By Alexandra Pecci • June 1, 2022

Cell and gene therapy advances coming fast and furious

A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.

By Kelly Bilodeau • June 1, 2022

SIGA prepares to kick production for monkeypox treatment into high gear

‘We’re not bored,’ the company’s science chief says as SIGA Technologies looks to ramp up supplies of its therapeutic.

By Meagan Parrish • May 31, 2022

First 90 Days: Sosei Heptares’ Chris Cargill

The company’s new CEO is looking to drive growth through collaboration and transparency.

By Kim Ribbink • May 31, 2022

PBMs under fire for drug prices defend their worth

A new Senate bill is putting PBMs in the crosshairs of lawmakers — but they argue that they're more than just middlemen.

By Michael Gibney • May 26, 2022